Home > Insider Trading > Filing (0001179110-15-006891)

Filing Details

Accession Number:: 0001179110-15-006891
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-04-30 21:17:02
Reporting Period:: 2015-04-29

Filing Date:: 2015-04-30
Accepted Time:: 2015-04-30 21:17:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1436304	Kythera Biopharmaceuticals Inc	KYTH	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1416180	R Keith Leonard	30930 Russell Ranch Road 3Rd Floor Westlake Village CA 91362	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-04-29	14,662	$0.00	14,662	No	4	A	Direct
Common Stock	Disposition	2015-04-30	4,557	$45.21	10,105	No	4	S	Direct
Common Stock	Disposition	2015-04-30	1,000	$45.67	9,105	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	863,073	Indirect	See footnote
Common Stock	47,103	Indirect	See footnote
Common Stock	47,103	Indirect	See footnote
Common Stock	189	Indirect	See footnote
Common Stock	189	Indirect	See footnote

Footnotes

Shares held by Leonard Family Trust, dated August 28, 1996, Keith Richard Leonard, Jr. and Nanette LaRosa Leonard, Trustees.
Shares held by Keith Richard Leonard, Jr., Retained Annuity Trust, Dated 12 April, 2010, Keith Richard Leonard, Jr., Trustee.
Shares held by Nanette LaRosa Leonard, Retained Annuity Trust, Dated 12 April, 2010, Keith Richard Leonard, Jr., Trustee.
Shares held by Keith R. Leonard III. Keith R. Leonard III is the son of the Reporting Person.
Shares held by Nina R. Leonard. Nina R. Leonard is the daughter of the Reporting Person.
On January 22, 2014, the Reporting Person was granted 14,662 restricted stock units (RSUs), with 100% of the RSUs to vest upon approval of the Issuer's New Drug Application (NDA) by the U.S. Food and Drug Administration. The NDA was approved on April 29, 2015. The Reporting Person received one (1) share of Common Stock for each one (1) RSU upon vesting.
Sale of shares to satisfy tax withholding obligations in connection with the vesting of the RSUs.
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $44.57 to $45.46, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $45.51 to $45.76, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.